Efficacy of clinical prognostic factors on survival in patients with glioblastoma;Glioblastomali hastalarda, klinik parametrelerin yaflam süresi üzerine etkileri

Turkish Neurosurgery

Volumn 20, Issue 2, 2010, Pages 117-125

  Tugcu, Bekir ^a   Postalci, Lutfi Sinasi ^a   Gunaldi, Omur ^a   Tanriverdi, Osman ^a   Akdemir, Hidayet ^a  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Glioblastoma; Prognosis; Survival time

Indexed keywords

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BRAIN NEOPLASMS; CHILD; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDY; SEX RATIO; STATISTICS AND NUMERICAL DATA; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REOPERATION; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77953850696     PISSN: 10195149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ammirati M, Galicich JH, Arbit E. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607-614, 1987.
2. Barker FG 2nd, Chang SM, Gutin PH, Malec MK, McDermott MW, Prados MD, Wilson CB. Survival and functional status after resection of recurrent glioblastoma multiforme Neurosurgery. 42(4):709-720; discussion 720-723, 1998.
3. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19):10-14, 2003.
4. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59(9):1617-1625, 1987.
5. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88(1):1-10, 1998.
6. Fazeny-Dorner B, Wenzel C, Veitl M, Piribauer M, Rossler K, Dieckmann K, Ungersbock K, Marosi C. Survival and prognostic factors of patients with unresectable glioblastoma multiforme. Anticancer Drugs 14(4):305-312, 2003.
7. Gamburg ES, Regine WF, Patchell RA, Strottmann JM, Mohiuddin M, Young AB. The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 48(5):1359-1362, 2000.
8. Gehan EA, Walker MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 46:189-195, 1977.
9. Gilbert H, Kagan AR, Cassidy F, Wagner J, Fuchs K, Fox D, Macri I, Gilbert D, Rao A, Nussbaum H, Forsythe A, Eder J, Latino F, Youleles L, Chan P, Hintz BL. Glioblastoma multiforme is not a uniform disease! Cancer Clin Trials 4(1):87-89, 1981.
10. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9(1):29-38, 2008.
11. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27(1):65-73, 1996.
12. Harsh GR 4th, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21(5):615-621, 1987.
13. Hirano H, Asakura T, Yokoyama S, Kadota K, Kasamo S, Okahara K, Hirakawa W, Niiro M, Nakamura K, Nakayama M, Yamasaki I. The prognostic factors in astrocytic tumors: Analysis by the Kaplan-Meier method and the Weibull loglinear model [Article in Japanese]. No Shinkei Geka 24(9):809-15, 1996.
14. Hoshino T. Acommentary on the biology and growth kinetics of low-grade and high-grade gliomas. J Neurosurg. 61(5):895-900, 1984.
15. Hung KS, Howng SL. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans. J Neurosurg 99(5):886-92, 2003.
16. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 129(8):477-84, 2003.
17. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J, Nikolic N. Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol 27(2):195-204, 2004.
18. Kathleen R. Lamborn, Susan M. Chang, Michael D. Prados. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-Oncology 6(3):227-235, 2004.
19. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 74(1):27-37, 1991.
20. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D Sawaya RJ. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Neurosurg 95(2):190-198, 2001.
21. Mao Y, Desmeules M, Semenciw RM, Hill G, Gaudette L, Wigle DT. Increasing brain cancer rates in Canada. CMAJ 145(12):1583-91, 1991.
22. McKeran RO et Thomas DGT. The Clinical Studies of Glioma. In: Thomas DGT et Graham DI (eds), Brain tumors scientific Basis, Clinical Investigation, and Current Therapy. London: Butterworth: 194-230.
23. Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP. Brem H. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 55(3):195-204, 2001.
24. Roth JG, Elvidge AR. Glioblastoma multiforme: A clinical survey. J Neurosurg. 17:736-750, 1960.
25. Salcman M. Survival in glioblastoma: Historical perspective. Neurosurgery. 7(5):435-439, 1980.
26. Salcman M. Epidemiology and factors affecting survival. In Apuzzo MLJ (ed.) Malignant cerebral Glioma. Park Ridge, IL; American Association Neurological Surgeons 1980: 95-109.
27. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Longterm survival in patients with supratentorial glioblastoma. J Neurooncol 36(1):61-64,1998.
28. Sawaya R, Hammoud M, Schoppa D, Hess KR, Wu SZ, Shi WM, Wildrick DM. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42(5):1044-1055; discussion 1055-1056. 1998.
29. Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P. Longterm glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 25(3):197-201, 1998.
30. Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 46(2):183-188, 1999.
31. Shinojima N, Kochi M, Hamada J, Nakamura H, Yano S, Makino K, Tsuiki H, Tada K, Kuratsu J, Ishimaru Y, Ushio Y. The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101(2):219-226, 2004.
32. Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L, Pujol T, Acebes JJ, Ribalta T, Ferrer I, Graus F. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97(4):1063-1071, 2003.
33. Trouillas P, Menaud G, De The G, Aimard G, Devic M. Epidemiological study of primary tumors of the neuraxis in the Rhone-Alps region. Quantitative data on the etiology and geographical distribution of 1670 tumors], Rev Neurol 131(10):691-708. 1975.
34. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 49(3):333-343, 1978.
35. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 303(23):1323-1329, 1980.
36. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6(2):338-343, 1988.